Janney Montgomery Scott LLC decreased its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 2.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 83,351 shares of the exchange traded fund’s stock after selling 2,206 shares during the period. Janney Montgomery Scott LLC owned approximately 0.11% of SPDR S&P Biotech ETF worth $7,507,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in SPDR S&P Biotech ETF by 198.6% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock worth $911,825,000 after purchasing an additional 6,138,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth approximately $141,284,000. Assetmark Inc. boosted its stake in shares of SPDR S&P Biotech ETF by 72,653.0% in the 3rd quarter. Assetmark Inc. now owns 589,299 shares of the exchange traded fund’s stock worth $58,223,000 after buying an additional 588,489 shares during the last quarter. Sivik Global Healthcare LLC bought a new position in shares of SPDR S&P Biotech ETF in the third quarter valued at approximately $29,640,000. Finally, Mirae Asset Securities USA Inc. increased its position in shares of SPDR S&P Biotech ETF by 50.0% during the third quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after acquiring an additional 300,000 shares during the last quarter.
SPDR S&P Biotech ETF Trading Up 0.6 %
XBI stock opened at $93.18 on Wednesday. The stock has a market cap of $7.10 billion, a P/E ratio of 11.47 and a beta of 1.11. The stock’s fifty day simple moving average is $93.35 and its two-hundred day simple moving average is $96.83. SPDR S&P Biotech ETF has a 1-year low of $81.14 and a 1-year high of $105.47.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Why Invest in 5G? How to Invest in 5G Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Breakout Stocks: What They Are and How to Identify Them
- What Does the Future Hold for Eli Lilly?
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.